Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › GLUE

SILVERARC CAPITAL MANAGEMENT, LLC position in GLUE

MONTE ROSA THERAPEUTICS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 525,000 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.3M, representing 0.80% of its reported portfolio and ranking #34 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed GLUE holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)525.00K sh
Reported value held$6.26M
Portfolio Weight0.80%
First reportedQ3 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's GLUE position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in GLUE in Q3 2025 at 694,942 shares (US$5.1M). The position peaked in Q1 2026 at 2,002,040 shares, worth US$32.9M. Across 5 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 525,000 shares valued at US$6.3M — an increase of 225,000 shares quarter over quarter.. Notable position changes include a 95% increase in Q1 2026 (shares rose 47% over the following quarter), a 85% trim in Q2 2026 (shares fell 51% over the following quarter), a 75% increase in Q3 2026 (shares fell 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 694.94K $5.15M New
Q4 2025 1.03M $16.14M Add
Q1 2026 2.00M $32.93M Add
Q2 2026 300.00K $7.26M Reduce
Q3 2026 525.00K $6.26M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GLUE and 13F data

GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 65 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GLUE

All GLUE fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held GLUE?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed GLUE holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in GLUE?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 525.00K shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $6.26M, representing 0.80% of its reported portfolio and ranking #34.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling GLUE?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in GLUE. The position peaked in Q1 2026 at 2.00M shares.

Which other funds hold GLUE?

Other major institutional holders of GLUE include NEA Management Company, LLC, TCG Crossover Management, LLC, Vestal Point Capital, LP, among 65 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.